MESA LABORATORIES INC (MLAB) Fundamental Analysis & Valuation
NASDAQ:MLAB • US59064R1095
Current stock price
97.85 USD
+2.01 (+2.1%)
Last:
This MLAB fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. MLAB Profitability Analysis
1.1 Basic Checks
- In the past year MLAB was profitable.
- MLAB had a positive operating cash flow in the past year.
- The reported net income has been mixed in the past 5 years: MLAB reported negative net income in multiple years.
- MLAB had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
- Looking at the Return On Assets, with a value of 0.86%, MLAB is in the better half of the industry, outperforming 66.67% of the companies in the same industry.
- MLAB has a Return On Equity of 2.00%. This is in the better half of the industry: MLAB outperforms 68.42% of its industry peers.
- The Return On Invested Capital of MLAB (3.58%) is better than 66.67% of its industry peers.
- The Average Return On Invested Capital over the past 3 years for MLAB is significantly below the industry average of 11.38%.
- The last Return On Invested Capital (3.58%) for MLAB is above the 3 year average (2.10%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.86% | ||
| ROE | 2% | ||
| ROIC | 3.58% |
ROA(3y)-19.07%
ROA(5y)-11.28%
ROE(3y)-58.62%
ROE(5y)-34.92%
ROIC(3y)2.1%
ROIC(5y)1.72%
1.3 Margins
- MLAB has a Profit Margin of 1.51%. This is in the better half of the industry: MLAB outperforms 66.67% of its industry peers.
- With a decent Operating Margin value of 6.96%, MLAB is doing good in the industry, outperforming 61.40% of the companies in the same industry.
- MLAB's Operating Margin has improved in the last couple of years.
- The Gross Margin of MLAB (62.40%) is better than 80.70% of its industry peers.
- MLAB's Gross Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 6.96% | ||
| PM (TTM) | 1.51% | ||
| GM | 62.4% |
OM growth 3Y41.92%
OM growth 5Y1.93%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.16%
GM growth 5Y2.74%
2. MLAB Health Analysis
2.1 Basic Checks
- MLAB has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
- MLAB has more shares outstanding than it did 1 year ago.
- Compared to 5 years ago, MLAB has more shares outstanding
- Compared to 1 year ago, MLAB has an improved debt to assets ratio.
2.2 Solvency
- MLAB has an Altman-Z score of 1.54. This is a bad value and indicates that MLAB is not financially healthy and even has some risk of bankruptcy.
- MLAB's Altman-Z score of 1.54 is in line compared to the rest of the industry. MLAB outperforms 45.61% of its industry peers.
- MLAB has a debt to FCF ratio of 4.41. This is a neutral value as MLAB would need 4.41 years to pay back of all of its debts.
- With a decent Debt to FCF ratio value of 4.41, MLAB is doing good in the industry, outperforming 71.93% of the companies in the same industry.
- A Debt/Equity ratio of 0.86 indicates that MLAB is somewhat dependend on debt financing.
- MLAB's Debt to Equity ratio of 0.86 is on the low side compared to the rest of the industry. MLAB is outperformed by 78.95% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.86 | ||
| Debt/FCF | 4.41 | ||
| Altman-Z | 1.54 |
ROIC/WACC0.34
WACC10.45%
2.3 Liquidity
- MLAB has a Current Ratio of 1.94. This is a normal value and indicates that MLAB is financially healthy and should not expect problems in meeting its short term obligations.
- MLAB's Current ratio of 1.94 is on the low side compared to the rest of the industry. MLAB is outperformed by 64.91% of its industry peers.
- MLAB has a Quick Ratio of 1.45. This is a normal value and indicates that MLAB is financially healthy and should not expect problems in meeting its short term obligations.
- Looking at the Quick ratio, with a value of 1.45, MLAB is doing worse than 68.42% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.94 | ||
| Quick Ratio | 1.45 |
3. MLAB Growth Analysis
3.1 Past
- The earnings per share for MLAB have decreased strongly by -87.40% in the last year.
- MLAB shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -39.16% yearly.
- MLAB shows a small growth in Revenue. In the last year, the Revenue has grown by 4.12%.
- The Revenue has been growing by 15.41% on average over the past years. This is quite good.
EPS 1Y (TTM)-87.4%
EPS 3Y-62.71%
EPS 5Y-39.16%
EPS Q2Q%351.94%
Revenue 1Y (TTM)4.12%
Revenue growth 3Y9.35%
Revenue growth 5Y15.41%
Sales Q2Q%3.64%
3.2 Future
- MLAB is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 247.51% yearly.
- Based on estimates for the next years, MLAB will show a small growth in Revenue. The Revenue will grow by 4.11% on average per year.
EPS Next Y3244.14%
EPS Next 2Y354.08%
EPS Next 3Y247.51%
EPS Next 5YN/A
Revenue Next Year4.19%
Revenue Next 2Y4.8%
Revenue Next 3Y4.11%
Revenue Next 5YN/A
3.3 Evolution
- When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
- The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. MLAB Valuation Analysis
4.1 Price/Earnings Ratio
- The Price/Earnings ratio is 152.89, which means the current valuation is very expensive for MLAB.
- MLAB's Price/Earnings is on the same level as the industry average.
- Compared to an average S&P500 Price/Earnings ratio of 27.18, MLAB is valued quite expensively.
- Based on the Price/Forward Earnings ratio of 67.80, the valuation of MLAB can be described as expensive.
- Compared to the rest of the industry, the Price/Forward Earnings ratio of MLAB is on the same level as its industry peers.
- MLAB is valuated expensively when we compare the Price/Forward Earnings ratio to 37.96, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 152.89 | ||
| Fwd PE | 67.8 |
4.2 Price Multiples
- 78.95% of the companies in the same industry are more expensive than MLAB, based on the Enterprise Value to EBITDA ratio.
- MLAB's Price/Free Cash Flow ratio is rather cheap when compared to the industry. MLAB is cheaper than 89.47% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 14.33 | ||
| EV/EBITDA | 15.77 |
4.3 Compensation for Growth
- The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
- MLAB has a very decent profitability rating, which may justify a higher PE ratio.
- A more expensive valuation may be justified as MLAB's earnings are expected to grow with 247.51% in the coming years.
PEG (NY)0.05
PEG (5Y)N/A
EPS Next 2Y354.08%
EPS Next 3Y247.51%
5. MLAB Dividend Analysis
5.1 Amount
- MLAB has a yearly dividend return of 0.69%, which is pretty low.
- MLAB's Dividend Yield is rather good when compared to the industry average which is at 0.11. MLAB pays more dividend than 96.49% of the companies in the same industry.
- With a Dividend Yield of 0.69, MLAB pays less dividend than the S&P500 average, which is at 1.82.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.69% |
5.2 History
- The dividend of MLAB decreases each year by -0.50%.
- MLAB has paid a dividend for at least 10 years, which is a reliable track record.
- MLAB has not decreased their dividend for at least 10 years, which is a reliable track record.
Dividend Growth(5Y)-0.5%
Div Incr Years0
Div Non Decr Years22
5.3 Sustainability
- MLAB pays out 93.97% of its income as dividend. This is not a sustainable payout ratio.
DP93.97%
EPS Next 2Y354.08%
EPS Next 3Y247.51%
MLAB Fundamentals: All Metrics, Ratios and Statistics
NASDAQ:MLAB (4/13/2026, 8:00:01 PM)
97.85
+2.01 (+2.1%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)02-03 2026-02-03/bmo
Earnings (Next)05-26 2026-05-26/bmo
Inst Owners93.82%
Inst Owner Change0.08%
Ins Owners2.86%
Ins Owner Change3.15%
Market Cap540.13M
Revenue(TTM)247.54M
Net Income(TTM)3.73M
Analysts80
Price Target106.59 (8.93%)
Short Float %4.3%
Short Ratio2.05
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.69% |
Yearly Dividend0.64
Dividend Growth(5Y)-0.5%
DP93.97%
Div Incr Years0
Div Non Decr Years22
Ex-Date05-29 2026-05-29 (0.16)
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)153.03%
Min EPS beat(2)130.33%
Max EPS beat(2)175.74%
EPS beat(4)3
Avg EPS beat(4)44.77%
Min EPS beat(4)-217.83%
Max EPS beat(4)175.74%
EPS beat(8)5
Avg EPS beat(8)420.17%
EPS beat(12)6
Avg EPS beat(12)229.7%
EPS beat(16)8
Avg EPS beat(16)172.52%
Revenue beat(2)1
Avg Revenue beat(2)-0.59%
Min Revenue beat(2)-1.95%
Max Revenue beat(2)0.77%
Revenue beat(4)1
Avg Revenue beat(4)-1.45%
Min Revenue beat(4)-3.63%
Max Revenue beat(4)0.77%
Revenue beat(8)4
Avg Revenue beat(8)0.47%
Revenue beat(12)4
Avg Revenue beat(12)-1.22%
Revenue beat(16)6
Avg Revenue beat(16)-1.01%
PT rev (1m)0%
PT rev (3m)10%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-3.77%
EPS NY rev (1m)0%
EPS NY rev (3m)19.12%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)1.07%
Revenue NY rev (1m)0%
Revenue NY rev (3m)1.06%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 152.89 | ||
| Fwd PE | 67.8 | ||
| P/S | 2.18 | ||
| P/FCF | 14.33 | ||
| P/OCF | 13 | ||
| P/B | 2.89 | ||
| P/tB | N/A | ||
| EV/EBITDA | 15.77 |
EPS(TTM)0.64
EY0.65%
EPS(NY)1.44
Fwd EY1.48%
FCF(TTM)6.83
FCFY6.98%
OCF(TTM)7.52
OCFY7.69%
SpS44.84
BVpS33.82
TBVpS-16.71
PEG (NY)0.05
PEG (5Y)N/A
Graham Number22.07
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 0.86% | ||
| ROE | 2% | ||
| ROCE | 4.53% | ||
| ROIC | 3.58% | ||
| ROICexc | 3.87% | ||
| ROICexgc | 18.77% | ||
| OM | 6.96% | ||
| PM (TTM) | 1.51% | ||
| GM | 62.4% | ||
| FCFM | 15.23% |
ROA(3y)-19.07%
ROA(5y)-11.28%
ROE(3y)-58.62%
ROE(5y)-34.92%
ROIC(3y)2.1%
ROIC(5y)1.72%
ROICexc(3y)2.32%
ROICexc(5y)2.16%
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)2.66%
ROCE(5y)2.18%
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3Y111.19%
ROICexc growth 5Y22.93%
OM growth 3Y41.92%
OM growth 5Y1.93%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.16%
GM growth 5Y2.74%
F-Score6
Asset Turnover0.57
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.86 | ||
| Debt/FCF | 4.41 | ||
| Debt/EBITDA | 3.81 | ||
| Cap/Depr | 15.35% | ||
| Cap/Sales | 1.55% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 98.31% | ||
| Profit Quality | 1009.48% | ||
| Current Ratio | 1.94 | ||
| Quick Ratio | 1.45 | ||
| Altman-Z | 1.54 |
F-Score6
WACC10.45%
ROIC/WACC0.34
Cap/Depr(3y)13.3%
Cap/Depr(5y)13.77%
Cap/Sales(3y)1.71%
Cap/Sales(5y)1.8%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-87.4%
EPS 3Y-62.71%
EPS 5Y-39.16%
EPS Q2Q%351.94%
EPS Next Y3244.14%
EPS Next 2Y354.08%
EPS Next 3Y247.51%
EPS Next 5YN/A
Revenue 1Y (TTM)4.12%
Revenue growth 3Y9.35%
Revenue growth 5Y15.41%
Sales Q2Q%3.64%
Revenue Next Year4.19%
Revenue Next 2Y4.8%
Revenue Next 3Y4.11%
Revenue Next 5YN/A
EBIT growth 1Y-4.88%
EBIT growth 3Y55.19%
EBIT growth 5Y17.63%
EBIT Next Year193.28%
EBIT Next 3Y47.61%
EBIT Next 5YN/A
FCF growth 1Y-7.43%
FCF growth 3Y6.74%
FCF growth 5Y10.67%
OCF growth 1Y-5.11%
OCF growth 3Y6.07%
OCF growth 5Y11.64%
MESA LABORATORIES INC / MLAB Fundamental Analysis FAQ
Can you provide the ChartMill fundamental rating for MESA LABORATORIES INC?
ChartMill assigns a fundamental rating of 5 / 10 to MLAB.
What is the valuation status of MESA LABORATORIES INC (MLAB) stock?
ChartMill assigns a valuation rating of 5 / 10 to MESA LABORATORIES INC (MLAB). This can be considered as Fairly Valued.
Can you provide the profitability details for MESA LABORATORIES INC?
MESA LABORATORIES INC (MLAB) has a profitability rating of 7 / 10.
Can you provide the PE and PB ratios for MLAB stock?
The Price/Earnings (PE) ratio for MESA LABORATORIES INC (MLAB) is 152.89 and the Price/Book (PB) ratio is 2.89.
Can you provide the expected EPS growth for MLAB stock?
The Earnings per Share (EPS) of MESA LABORATORIES INC (MLAB) is expected to grow by 3244.14% in the next year.